OncLive

Tumor Markers in CCA

Chemotherapy for Advanced Lung Cancer

Dr. Mutch Discusses Radiation Versus Targeted Therapy in Endometrial Cancer

Dr. Advani Discusses CD30 as a Target and Brentuximab Vedotin in ALCL

The Role of Venetoclax + Rituximab in CLL

Beth Sandy on Olanzapine as a Treatment for Chemotherapy-Induced Nausea and Vomiting

Exercise and Lifestyle Factors in Patients with mCRC

Next-Generation ALK-Targeted Agents in NSCLC

Pathologic Classification of Neuroendocrine Tumors

Dr. Goldberg on Managing CNS Metastases in Oncogene-Driven NSCLC

Dr. Patel on Induction Therapy With Bendamustine and Rituximab in MCL

Dr. Andrew Zelenetz on the Impact of Rituximab in Lymphoma

Dr. Ilson on Chemotherapy in Advanced Gastric Cancer

Neoadjuvant Treatment for Triple-Negative Breast Cancer

Dr Al Malki on Outcomes With PTCy-Based GVHD Prophylaxis in Hematologic Malignancies

Dr. Gubens on Prevalence of EGFR/ALK/ROS1 and PD-L1 Expression in NSCLC

Dr. Kondziolka on Therapy for Patients With Melanoma Who Have Brain Mets

Navigating Through Testicular Cancer Treatment

Customizing Imaging Based on Calcitonin Levels in Medullary Thyroid Cancer

Dr. Fox Discusses Genomic Testing in Breast Cancer

The Future of ITP Treatment

Dr. Wallen on Technological Advances in NSCLC

Dr. Robert Dreicer on Drug Development Challenges in Prostate Cancer

Counseling Patients on Goals of Therapy in ITP

Dr. Merritt on Robotic Lobectomy Versus VATS and Open Thoracotomy in NSCLC

Duration of Rituximab Maintenance in FL

Impressive Findings for Next-Generation EGFR Inhibitors

Dr. Levine on Immunotherapy in Endometrial Cancer

Practical Considerations for Subcutaneous Rituximab

Memarzadeh on Hormonal Therapy for Endometrial Tumors

Dr. Sartor Discusses PSA Testing for Prostate Cancer

Dr. Riess on ROS1 Fusions in Lung Cancer

Dr. Decker on Stereotactic Body Radiation Therapy in Lung Cancer

Targeting HER2 Outside of Breast Cancer

Dr. Susan O’Brien on Next-Generation Small Molecules in CLL

Dr. Eckhardt on the Wnt Pathway in Colorectal Cancer

The Importance of NGS Testing in NSCLC

Dr. Tan on the Risk of Novel Coronavirus for Patients With Cancer

Multiparametric MRI for Prostate Cancer Diagnosis

Dr. Burns on Identifying Genetic Alterations in Lung Cancer

Dr. Ginsburg Discusses the Use of VIA in Cervical Cancer Screening

The Broad Spectrum of MDS

Prognostic and Predictive Factors in Renal Cell Carcinoma

Dr. Jagannath on Immunotherapy in Multiple Myeloma

Dr. Ferguson on Treatment Options for Early-Stage Cervical Cancer

Dr. Bollard on the Treatment of EBV-Positive Lymphoma

Practical Experience With Optune in Glioblastoma

Dr. Goldman on the Use of Immunotherapy in Oncogene-Driven NSCLC

The Role of Patient Education in Side Effect Management

BRAF Mutations in Colorectal Cancer

Dr. Osman on the 29th Miami Breast Cancer Conference